Inspection (17)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revised schedule for reporting holding statements due to live trading session on Sunday, February 01, 2026 during Union Budget presentation. | |||||||||||||||
Revised schedule for reporting holding statements due to live trading session on Sunday, February 01, 2026 during Union Budget presentation.
| |||||||||||||||
SEBI adjudication order against Research Guru (Investment Adviser) and its operator Abhishek Sharma for multiple violations of Investment … | |||||||||||||||
SEBI adjudication order against Research Guru (Investment Adviser) and its operator Abhishek Sharma for multiple violations of Investment Advisers Regulations, Code of Conduct, and fraudulent trade practices.
| |||||||||||||||
NSE reminds trading members to submit mandatory Cyber Security & Cyber Resilience Audit Report for H2 2025 by January 31, 2026, to avoid … | |||||||||||||||
NSE reminds trading members to submit mandatory Cyber Security & Cyber Resilience Audit Report for H2 2025 by January 31, 2026, to avoid penalties.
| |||||||||||||||
NSE reminds trading members to submit Action Taken Reports for non-compliances identified in internal audit reports for the half year ended … | |||||||||||||||
NSE reminds trading members to submit Action Taken Reports for non-compliances identified in internal audit reports for the half year ended September 30, 2025, by January 31, 2026, with monetary penalties for non-compliance.
| |||||||||||||||
NATCO Pharma provides clarification on ongoing litigation news, while Cipla addresses USFDA Form 483 inspectional observations at supply … | |||||||||||||||
NATCO Pharma provides clarification on ongoing litigation news, while Cipla addresses USFDA Form 483 inspectional observations at supply partner Pharmathen's Greece facility.
| |||||||||||||||
NATCO Pharma clarifies ongoing litigation with no current material impact, while Cipla addresses USFDA Form 483 observations at partner … | |||||||||||||||
NATCO Pharma clarifies ongoing litigation with no current material impact, while Cipla addresses USFDA Form 483 observations at partner facility Pharmathen manufacturing Lanreotide Injection.
| |||||||||||||||
SEBI issues notices of attachment (15137 & 15138 of 2026) for bank accounts and demat accounts of Mr. Mahesh Kumar Sharma for recovery under … | |||||||||||||||
SEBI issues notices of attachment (15137 & 15138 of 2026) for bank accounts and demat accounts of Mr. Mahesh Kumar Sharma for recovery under RC No. 8969 of 2025 relating to CIG Realty Fund Schemes.
| |||||||||||||||
Trading members using SaaS-based solutions must submit half-yearly compliance reports through NSE Member Portal for the period July 01, 2025 … | |||||||||||||||
Trading members using SaaS-based solutions must submit half-yearly compliance reports through NSE Member Portal for the period July 01, 2025 to December 31, 2025 by January 31, 2026.
| |||||||||||||||
NSE mandates trading members to report cyber incidents for Q4 2025 by January 15, 2026 through member portal under SEBI's Cyber Security & … | |||||||||||||||
NSE mandates trading members to report cyber incidents for Q4 2025 by January 15, 2026 through member portal under SEBI's Cyber Security & Cyber Resilience framework.
| |||||||||||||||
SEBI imposed penalty on Samdhyan Commodities Brokers Private Limited for violations related to unverified trading terminals at Authorized … | |||||||||||||||
SEBI imposed penalty on Samdhyan Commodities Brokers Private Limited for violations related to unverified trading terminals at Authorized Person locations during inspection conducted on January 6, 2025.
| |||||||||||||||